Equity Overview
Price & Market Data
Price: $0.71
Daily Change: +$0.0203 / 2.86%
Range: $0.469 - $0.742
Market Cap: $23,569,354
Volume: 4,811,661
Performance Metrics
1 Week: 144.6%
1 Month: 122.9%
3 Months: 87.95%
6 Months: -80.33%
1 Year: -81.55%
YTD: 37.35%
Company Details
Employees: 17
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial in patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company is headquartered in Coral Gables, Florida.